Table 6.
OS | |||
---|---|---|---|
Variables | Hazard ratio | 95% CI | P‐value |
PS (0 vs.1,2) | 2.57 | 1.23–5.36 | 0.01 |
Stage (IIIA, IIIB vs. IV) | 3.42 | 0.95–12.28 | 0.06 |
EGFR mutation status (mutation vs. wild‐type, unknown) | 1.44 | 0.63–3.31 | 0.39 |
Number of regimens before AMR (<3 vs. ≥ 3) | 1.07 | 0.51–2.25 | 0.86 |
Response to AMR (PR vs. SD, PD) | 3.58 | 0.94–13.54 | 0.06 |
topoisomerase‐II (low vs. high) | 2.88 | 1.23–6.76 | 0.01 |
AMR, amrubicin; HR, hazard ratio; OS, overall survival; CI, confidence interval; CR, complete response; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.